6.4.5.2. management psa failures radiation therapy. therapeutic options patients adt salvage local procedures, well ‘wait see’ approach, based eau bcr risk categories relapse. sr meta-analysis included studies comparing efficacy toxicity salvage rp, salvage hifu, salvage cryotherapy, sbrt, salvage ldr bt, salvage hdr bt management locally recurrent pca primary radical ebrt . outcomes bcr-free survival two five years. significant differences regards recurrence-free survival (rfs) modalities found. five-year rfs ranged 50% cryotherapy 60% hdr bt sbrt. authors reported severe gu toxicity exceeded 21% hifu rp, whereas ranged 4.2% 8.1% re-irradiation. differences severe gi toxicity also appeared favour re-irradiation, particularly hdr bt . due methodological limitations review (the majority included studies uncontrolled single-arm case series considerable heterogeneity definitions core outcomes) available evidence treatment options low quality strong recommendations regarding choice techniques cannot made. following overview important findings techniques. 6.4.5.2.1. salvage radical prostatectomy salvage rp rt associated higher likelihood aes compared primary surgery risk fibrosis poor wound healing due radiation . 6.4.5.2.1.1. oncological outcomes sr literature, chade, et al., showed srp provided five ten years bcr-free survival estimates ranging 47–82% 28–53%, respectively. ten-year css os rates ranged 70–83% 54–89%, respectively. pre-srp psa value prostate biopsy isup grade group strongest predictors presence organ-confined disease, progression, css . multi-centre analysis including 414 patients, five-year bcr-free survival, css os 56.7%, 97.7% 92.1%, respectively . pathological stage ≥ t3b (or: 2.348) gs (up 7.183 gs > 8) independent predictors bcr (see table 6.4.7). table 6.4.7: oncological results selected salvage radical prostatectomy case series studynmedian fu (mo)pathologic organ-confined (%)psm (%)lymph-node involvement (%)bcr-free probability (%)css (%)time probabilitychade, et al. 2011 40455552516378310 yr.mandel, et al. 2016 553650272249895 yr.ogaya-pinies,et al. 2018 96145017885*-14 mo.marra, et al. 2021 4143646301657985 yr. *percentage patients without bcr.bcr = biochemical recurrence; css = cancer-specific survival; fu = follow-up; mo = months; n = number patients; psm = positive surgical margin; yr. = year. 6.4.5.2.1.2. morbidity compared primary open rp, srp associated higher risk later anastomotic stricture (47 vs. 5.8%), urinary retention (25.3% vs. 3.5%), urinary fistula (4.1% vs. 0.06%), abscess (3.2% vs. 0.7%) rectal injury (9.2 vs. 0.6%) . series, complications appear less common . functional outcomes also worse compared primary surgery, urinary incontinence ranging 21% 90% ed nearly patients . 6.4.5.2.1.3. summary salvage radical prostatectomy general, srp considered patients low co-morbidity, life expectancy least ten years, pre-srp psa < 10 ng/ml initial biopsy isup grade group ≤ 2/3, ln involvement evidence distant metastatic disease pre-srp, whose initial clinical staging t1 t2 . 6.4.5.2.2. salvage cryoablation prostate 6.4.5.2.2.1. oncological outcomes salvage cryoablation prostate (scap) proposed alternative salvage rp, potentially lower risk morbidity equal efficacy. sr total 32 studies assessed scap, recruiting total 5,513 patients. overwhelming majority patients (93%) received whole-gland scap. adjusted pooled analysis two-year bcr-free survival scap 67.49% (95% ci: 61.68–72.81%), five-year bcr-free survival 50.25% (95% ci: 44.10–56.40%). however, certainty evidence low. table 6.3.8 summarises results selection largest series scap date relation oncological outcomes (bcr only) (table 6.4.8). table 6.4.8: oncological results selected salvage cryoablation prostate case series, including least 250 patients studynmedian fu (mo)time point outcome measurement (yr)bcr-free probabilitydefinition failureginsburg, et al. 2017 89819.0571.3%phoenix criteriaspiess, et al. 2010 45040.83.439.6%psa > 0.5 ng/mlli, et al. 2015 48618.2563.8%phoenix criteriakovac, et al. 2016 48618.2575.5%(nadir psa < 0.4 ng/ml);22.1%(nadir psa > 0.4 ng/ml)phoenix criteriaahmad, et al. 2013 28323.9367.0%(nadir psa < 1 ng/ml);14.0%(nadir psa > 1 ng/ml)phoenix criteriapisters, et al. 2008 27921.6558.9% (astro)54.5% (phoenix)astro phoenix criteria astro = american society therapeutic radiology oncology; bcr = biochemical recurrence;fu = follow-up; mo. = months; n = number patients; psa = prostate-specific antigen; yr. = year. 6.4.5.2.3. salvage re-irradiation 6.4.5.2.3.1. salvage brachytherapy radiotherapy failure carefully selected patients good ps, primary localised pca, good urinary function histologically proven local recurrence candidates salvage bt using either hdr ldr. sr total sixteen studies (four prospective) 32 studies (two prospective) assessed salvage hdr ldr bt, respectively, majority (> 85%) receiving whole-gland bt rather focal treatment . adjusted pooled analysis two-year bcr-free survival hdr 77% (95% ci: 70–83%) ldr 81% (95% ci:74–86%). five-year bcr-free survival hdr 60% (95% ci: 52–67%) ldr 56% (95% ci: 48–63%). noted above, bt techniques associated lower rates severe gu toxicity compared rp hifu, 8% hdr (95% ci: 5.1–11%) 8.1% ldr (95% ci: 4.3–13%). rates severe gi toxicity reported low 0% hdr (95% ci: 0–0.2%) 1.5% ldr (95% ci: 0.2–3.4%). high-dose-rate ldr bt effective treatment options acceptable toxicity profile. however, published series small likely under-report toxicity. consequently, treatment offered experienced centres ideally within randomised clinical trials prospective registry studies (see table 6.4.9). table 6.4.9: treatment-related toxicity bcr-free probability selected salvage brachytherapy studies including least 100 patients. studystudy designn bt typemedian fu (mo)treatment toxicitybcr-free probabilitylopez, et al. 2019 multi-centre retrospective75 hdr44 ldr5223.5% late g3+ gu5 yr 71%(95% ci: 65.9-75.9%)crook, et al. 2019 multi-centre prospective100 ldr5414% late g3 combined gi/gun.r.smith, et al. 2020 single-centre retrospective108 ldr7615.7%/2.8% late g3 gu/gi5 yr. 63.1%10 yr. 52%lyczek, et al. 2009 single-centre retrospective115 hdrn.r.12.2%/0.9%late g3+ gu/gi60% 40 mo. bt = brachytherapy; ci = confidence interval; g = grade; gi = gastro-intestinal; gu = genito-urinary; hdr = high-dose rate; ldr = low-dose rate; mo = months; n = number patients; n.r. = reported; yr = year. 6.4.5.2.3.2. salvage stereotactic ablative body radiotherapy radiotherapy failure 6.4.5.2.3.2.1.oncological outcomes morbidity stereotactic ablative body radiotherapy (cyberknife® linac-based treatment) potentially viable new option treat local recurrence rt. carefully selected patients good ipss-score, without obstruction, good ps histologically proven localised local recurrence potential candidates sabr. metaanalysis sr five mostly retrospective studies including 206 patients treated cyberknife® linac-based treatment showing two-year rfs estimates (61.6%, 95% ci: 52.6–69.9%) . retrospective multi-centre study (n = 100) median pre-salvage psa 4.3 ng/ml 34% patients received adt twelve months (median). recurrences biopsy proven. patients treated cyberknife® single dose 6 gy six daily fractions (total dose 36 gy). median followup 30 months estimated three-year second bcr-free survival 55% . smaller retrospective series including 50 men histologically proven local recurrence median pre-salvage psa 3.9 ng/ml 15% received additional adt. estimated five-year second bcr-free survival 60% (median follow-up 44 months) outcome comparable series treating patients rp, hifu bt . table 6.4.10 summarises results two larger sabr series addressing oncological outcomes morbidity. table 6.4.10: treatment-related toxicity bcr-free survival selected sabr studies studystudy designn rt-typemedian fu (mo)fractionation(sd/td)adttreatment toxicitybcr-free survivalbergamin, et al. 2020 single-centre prospective25linacbased25sd 6-6.2td 36-38 gy0/252 yr. lateg1 gi 8%g2 gu 4%2 yr. 80%fuller, et al. 2020 single-centre retrospective50cyber knife44sd 6.8 gytd 34 gy7/505 yr: 8% late g3+ gu5 yr. 60%pasquier, et al. 2020 multi-centre retrospective100cyber knife30sd 6 gytd 36 gy34/100median 12 mo.3 yr. grade 2+ gu 20.8%gi 1%3 yr. 55% bcr = biochemical recurrence; fu = follow-up; mo = months; n = number patients; rt-type = type radio-therapy; sd = single dose; td = total dose; yr = year. 6.4.5.2.3.2.2.morbidity retrospective single-centre study 50 consecutive patients chronic significant toxicity seen gu domain five-year grade 2+ grade 3+ gu rates 17% 8%, respectively. gi toxicity > grade 1 seen. note, fifteen patients sexually potent pre-salvage sbrt, twelve subsequently lost potency . retrospective french (getug) multi-centre series (n = 100) three-year late grade 2+ gu gi toxicity 20.8% (95% ci: 13–29%) 1% (95% ci: 0.1–5.1%), respectively . 6.4.5.2.3.2.3.summary salvage stereotactic ablative body radiotherapy despite encouraging results far number patients treated sabr relatively limited. view rates higher grade 2+ gu side effects, sabr offered selected patients, experienced centres part clinical trial well-designed prospective study. 6.4.5.2.4. salvage high-intensity focused ultrasound 6.4.5.2.4.1. oncological outcomes salvage hifu emerged alternative thermal ablation option radiation-recurrent pca. relatively newer scap data salvage hifu even limited. sr metaanalysis included 20 studies (n = 1,783) assessing salvage hifu . overwhelming majority patients (86%) received whole-gland salvage hifu. adjusted pooled analysis two-year bcr-free survival salvage hifu 54.14% (95% ci: 47.77–60.38%) five-year bcr-free survival 52.72% (95% ci: 42.66– 62.56%). however, certainty evidence low. table 6.4.11 summarises results selection largest series salvage hifu date relation oncological outcomes (bcr only). table 6.4.11: oncological results selected salvage cryoablation prostate case series, including least 250 patients studynmedian fu (mo)time point outcome measurement (yr)bcr-free probabilitydefinition failurecrouzet, et al.2017 41839.6549.0%phoenix criteriamurat, et al.2009 167mean 18.1325.0% (high-risk)53.0% (low-risk)*phoenix criteria positive biopsy initiation post-hifu salvage therapykanthabalan, et al. 2017 15035.0348.0%phoenix criteriajones, et al.2018 10012.0150.0%nadir psa > 0.5 ng/ml positive biopsy *results stratified pre-ebrt d’amico risk groups.bcr = biochemical recurrence; fu = follow-up; mo = months; n = number patients; yr = year. 6.4.5.2.4.2. morbidity main adverse effects complications relating salvage hifu include urinary incontinence, urinary retention due bladder outflow obstruction, rectourethral fistula ed. sr meta-analysis showed adjusted pooled analysis severe gu toxicity salvage hifu 22.66% (95% ci: 16.98–28.85%) . certainty evidence low. table 6.4.12 summarises results selection largest series salvage hifu date relation gu outcomes. table 6.4.12: peri-operative morbidity, erectile function urinary incontinence selected salvage hifu case series, including least 100 patients studyntime point outcome measurement (yr)incontinence* (%)obstruction/retention (%)rectourethralfistula (%)ed (%)crouzet, et al.2017 418median 39.642.318.02.3n.r.murat, et al.2009 167median 18.149.57.83.0n.r.kanthabalan, et al. 2017 1502412.58.02.041.7jones, et al.2018 1001242.049.05.074.0 *incontinence heterogeneously defined; figures represent least 1 pad usage. ed = erectile dysfunction; n.r. = reported; n = number patients. 6.4.5.2.4.3. summary salvage high-intensity focused ultrasound lack high-certainty data prohibits recommendations regarding indications salvage hifu routine clinical practice. also risk significant morbidity associated use salvage setting. consequently, salvage hifu performed selected patients experienced centres part clinical trial well-designed prospective cohort study.